JP4196829B2 - 5,8,14−トリアザテトラシクロ[10.3.1.02,11.04,9]−ヘキサデカ−2(11),3,5,7,9−ペンタエンのコハク酸塩およびその医薬組成物 - Google Patents
5,8,14−トリアザテトラシクロ[10.3.1.02,11.04,9]−ヘキサデカ−2(11),3,5,7,9−ペンタエンのコハク酸塩およびその医薬組成物 Download PDFInfo
- Publication number
- JP4196829B2 JP4196829B2 JP2003546896A JP2003546896A JP4196829B2 JP 4196829 B2 JP4196829 B2 JP 4196829B2 JP 2003546896 A JP2003546896 A JP 2003546896A JP 2003546896 A JP2003546896 A JP 2003546896A JP 4196829 B2 JP4196829 B2 JP 4196829B2
- Authority
- JP
- Japan
- Prior art keywords
- pentaene
- hexadeca
- succinate
- ray diffraction
- diffraction pattern
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/18—Bridged systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4995—Pyrazines or piperazines forming part of bridged ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A61P25/10—Antiepileptics; Anticonvulsants for petit-mal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
- C07D487/18—Bridged systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Addiction (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Psychology (AREA)
- Diabetes (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Child & Adolescent Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Description
本発明は、5,8,14−トリアザテトラシクロ[10.3.1.02,11.04,9]−ヘキサデカ−2(11),3,5,7,9−ペンタエンのコハク酸塩に関する。特に本発明は、このコハク酸塩の無水物および水和物形態に関する。
(i)適切な溶媒中の5,8,14−トリアザテトラシクロ[10.3.1.02,11.04,9]−ヘキサデカ−2(11),3,5,7,9−ペンタエンをコハク酸と接触させ、そして
(ii)生成された結晶を収集する
過程を包含する方法にも関する。
化合物5,8,14−トリアザテトラシクロ[10.3.1.02,11.04,9]−ヘキサデカ−2(11),3,5,7,9−ペンタエンは、多数のCNS疾患、障害および状態、特にニコチン依存、中毒および禁断症状の治療のためのニコチン部分アゴニストである。5,8,14−トリアザテトラシクロ[10.3.1.02,11.04,9]−ヘキサデカ−2(11),3,5,7,9−ペンタエンのコハク酸塩は、わずかに吸湿性であるだけであり、そして高い水溶解度を有する。これらの特徴のために、コハク酸塩は製剤処方物使用のために非常に適している。
示差走査熱量測定(DSC)により、本発明のコハク酸塩の固体状態熱行動を調べた。無水コハク酸塩に関する追跡を表2に示す。水和コハク酸塩に関しては図4に示す。Mettler ToledoDSC821e(STARe System)で、DSCサーモグラムを得た。一般に、小ピンホールを有する圧着アルミニウム鍋中で、1〜10 mgの試料を調製した。30〜300℃の範囲で5℃/分の加熱速度で、測定を実行した。
銅放射CuKα、固定スリット(1.0、1.0、0.6 mm)およびKevex固体状態検出器を装備したBruker D5000回析計(Bruker AXS, Madison, Wisconsin)を用いて、本発明のコハク酸塩に関する粉末X線回析パターンを収集した。0.04度の段階サイズおよび1.0秒の段階時間を用いて、2シータ(2θ)で3.0から40.0度までデータを収集した。
5,8,14−トリアザテトラシクロ[10.3.1.0 2,11 .0 4,9 ]−ヘキサデカ−2(11),3,5,7,9−ペンタエンの無水コハク酸塩
5,8,14−トリアザテトラシクロ[10.3.1.0 2,11 .0 4,9 ]−ヘキサデカ−2(11),3,5,7,9−ペンタエンのコハク酸塩水和物
反応器に、実施例1で調製した無水コハク酸塩および水(500 mL)を投入した。懸濁液を約40℃で約12時間撹拌した。結晶生成物を濾過し、真空乾燥して、コハク酸水和物塩を得た。
Claims (8)
- 5,8,14−トリアザテトラシクロ[10.3.1.02,11.04,9]−ヘキサデカ−2(11),3,5,7,9−ペンタエンのコハク酸塩。
- 前記塩が無水である、請求項1記載の化合物。
- 銅放射を用いて測定した場合に 13.3および17.2の2θのX線回析パターンピークを実質的に特徴とするX線回析パターンを有する、請求項2記載の化合物。
- 198℃での融解/分解遷移の開始を特徴とする、請求項2記載の化合物。
- 前記塩が水和物である、請求項1記載の化合物。
- 銅放射を用いて測定した場合に 13.0、16.5および19.0の2θのX線回析パターンピークを特徴とするX線回析パターンを有する、請求項6記載の化合物。
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US33424501P | 2001-11-29 | 2001-11-29 | |
PCT/IB2002/004380 WO2003045394A1 (en) | 2001-11-29 | 2002-10-21 | Succinic acid salts of 5,8,14-triazatetracyclo'10.3.1.0<2,11>.0<4,9>-hexadeca-2(11),3,5,7,9-pentaene and pharmaceutical compositions thereof |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2005513032A JP2005513032A (ja) | 2005-05-12 |
JP4196829B2 true JP4196829B2 (ja) | 2008-12-17 |
Family
ID=23306297
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2003546896A Expired - Fee Related JP4196829B2 (ja) | 2001-11-29 | 2002-10-21 | 5,8,14−トリアザテトラシクロ[10.3.1.02,11.04,9]−ヘキサデカ−2(11),3,5,7,9−ペンタエンのコハク酸塩およびその医薬組成物 |
Country Status (26)
Country | Link |
---|---|
US (1) | US6794388B2 (ja) |
EP (1) | EP1461040B1 (ja) |
JP (1) | JP4196829B2 (ja) |
KR (1) | KR20040066140A (ja) |
CN (1) | CN1589148A (ja) |
AR (1) | AR037677A1 (ja) |
AT (1) | ATE320256T1 (ja) |
AU (1) | AU2002341327A1 (ja) |
BR (1) | BR0214559A (ja) |
CA (1) | CA2468705A1 (ja) |
DE (1) | DE60209929T2 (ja) |
DO (1) | DOP2002000512A (ja) |
ES (1) | ES2258652T3 (ja) |
GT (1) | GT200200236A (ja) |
HN (1) | HN2002000332A (ja) |
IL (1) | IL161326A0 (ja) |
MX (1) | MXPA04003192A (ja) |
PA (1) | PA8559401A1 (ja) |
PE (1) | PE20030738A1 (ja) |
PL (1) | PL374325A1 (ja) |
RU (1) | RU2004116311A (ja) |
SV (1) | SV2004001413A (ja) |
TW (1) | TW200300345A (ja) |
UY (1) | UY27548A1 (ja) |
WO (1) | WO2003045394A1 (ja) |
ZA (1) | ZA200402720B (ja) |
Families Citing this family (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE69839131T3 (de) * | 1997-12-31 | 2015-05-07 | Pfizer Products Inc. | Arylkondensierte azapolycyclische derivate |
EP1628685B1 (en) | 2003-04-25 | 2010-12-08 | Gilead Sciences, Inc. | Antiviral phosphonate analogs |
WO2004103372A1 (en) * | 2003-05-20 | 2004-12-02 | Pfizer Products Inc. | Pharmaceutical compositions of varenicline |
RU2317295C1 (ru) * | 2003-10-27 | 2008-02-20 | Мерк Энд Ко., Инк. | Соль антагониста ccr-2 |
ME01945B (me) | 2004-07-27 | 2011-12-31 | Gilead Sciences Inc | Nukleozid-fosfonatni konjugati kao sredstva protiv hiv-a |
US20110086086A1 (en) * | 2005-07-26 | 2011-04-14 | Pfizer Inc | Transdermal system for varenicline |
KR100734147B1 (ko) * | 2005-07-29 | 2007-07-02 | 주식회사 엘지데이콤 | 호 알림 지연을 통한 멀티미디어 통화연결음 서비스 시스템및 방법 |
US20090258840A1 (en) * | 2006-05-16 | 2009-10-15 | Gilead Sciences, Inc. | Method and compositions for treating hematological malignancies |
MX2009005043A (es) * | 2006-11-09 | 2009-05-25 | Pfizer Prod Inc | Polimorfos de intermedios nicotinicos. |
DK2125786T3 (da) * | 2006-12-21 | 2011-05-09 | Pfizer Prod Inc | Succinatsalt af 2-((4-(1-methyl-4-(pyridin-4-yl)-1H-pyrazol-3-yl) phenoxy)methyl) quinolin |
US8440825B2 (en) | 2008-03-06 | 2013-05-14 | Medichem S.A. | Fumaric acid salt of varenicline |
EP2268639A2 (en) | 2008-05-22 | 2011-01-05 | Teva Pharmaceutical Industries Ltd. | Varenicline tosylate, an intermediate in the preparation process of varenicline l-tartrate |
US20090318460A1 (en) * | 2008-05-26 | 2009-12-24 | Glenmark | Amorphous varenicline tartrate and process for the preparation thereof |
PT2307435E (pt) * | 2008-07-08 | 2012-09-19 | Gilead Sciences Inc | Sais de compostos inibidores de vih |
US20100010221A1 (en) * | 2008-07-10 | 2010-01-14 | Revital Lifshitz-Liron | Processes for purifying varenicline l-tartrate salt and preparing crystalline forms of varenicline l-tartrate salt |
WO2010033045A1 (en) * | 2008-09-16 | 2010-03-25 | Igor Anatolievich Pomytkin | Compositions and methods for prevention or treatment of beta amyloid deposition |
PT2376499E (pt) * | 2008-12-11 | 2015-06-03 | Cti Biopharma Corp | Sal citrato de 11-(2-pirrolidin-1-il-etoxi)-14,19-dioxa- 5,7,26-triaza-tetraciclo[19.3.1.1(2,6)1(8,12)]heptacosa- 1(25),2(26),3,5,8,10,1 (27),16,21,23-decaeno |
WO2010143070A2 (en) | 2009-06-10 | 2010-12-16 | Actavis Group Ptc Ehf | Amorphous varenicline tartrate co-precipitates |
WO2010151524A1 (en) | 2009-06-22 | 2010-12-29 | Teva Pharmaceutical Industries Ltd | Solid states forms of varenicline salts and processes for preparation thereof |
WO2011140431A1 (en) | 2010-05-06 | 2011-11-10 | Teva Pharmaceutical Industries Ltd. | Varenicline salts and crystal forms thereof |
CN104334561B (zh) | 2012-04-13 | 2016-06-22 | 连云港金康和信药业有限公司 | 化合物jk12a及其制备 |
IL251769B (en) | 2014-10-20 | 2022-06-01 | Oyster Point Pharma Inc | Varnicline compound for use as a drug for treating dry eye, increasing tear production and treating eye discomfort and a premebacte preparation containing Varnicline |
TW202320785A (zh) | 2016-04-07 | 2023-06-01 | 美商奧伊斯特普安生物製藥公司 | 治療眼部病狀之方法 |
US10851125B2 (en) | 2017-08-01 | 2020-12-01 | Gilead Sciences, Inc. | Crystalline forms of ethyl ((S)-((((2R,5R)-5-(6-amino-9H-purin-9-yl)-4-fluoro-2,5-dihydrofuran-2-yl)oxy)methyl)(phenoxy)phosphoryl(-L-alaninate |
WO2018154395A2 (en) | 2018-06-11 | 2018-08-30 | Alvogen Malta Operations (Row) Ltd | Controlled release pharmaceutical composition of varenicline |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE69839131T3 (de) * | 1997-12-31 | 2015-05-07 | Pfizer Products Inc. | Arylkondensierte azapolycyclische derivate |
ATE376838T1 (de) | 1999-08-27 | 2007-11-15 | Inex Pharmaceuticals Corp | Zusammensetzungen zur stimulation der zytokin sekretion und zur induktion einer immunantwort |
YU34501A (sh) * | 2000-05-26 | 2003-10-31 | Pfizer Products Inc. | Postupak reaktivne kristalizacije radi povećanja veličine čestica |
-
2002
- 2002-10-21 CN CNA028229304A patent/CN1589148A/zh active Pending
- 2002-10-21 JP JP2003546896A patent/JP4196829B2/ja not_active Expired - Fee Related
- 2002-10-21 PL PL02374325A patent/PL374325A1/xx not_active Application Discontinuation
- 2002-10-21 KR KR10-2004-7008116A patent/KR20040066140A/ko not_active Application Discontinuation
- 2002-10-21 AT AT02775143T patent/ATE320256T1/de not_active IP Right Cessation
- 2002-10-21 WO PCT/IB2002/004380 patent/WO2003045394A1/en active IP Right Grant
- 2002-10-21 RU RU2004116311/04A patent/RU2004116311A/ru not_active Application Discontinuation
- 2002-10-21 EP EP02775143A patent/EP1461040B1/en not_active Expired - Lifetime
- 2002-10-21 CA CA002468705A patent/CA2468705A1/en not_active Abandoned
- 2002-10-21 DE DE60209929T patent/DE60209929T2/de not_active Expired - Fee Related
- 2002-10-21 IL IL16132602A patent/IL161326A0/xx unknown
- 2002-10-21 AU AU2002341327A patent/AU2002341327A1/en not_active Abandoned
- 2002-10-21 MX MXPA04003192A patent/MXPA04003192A/es active IP Right Grant
- 2002-10-21 BR BRPI0214559-6A patent/BR0214559A/pt not_active IP Right Cessation
- 2002-10-21 ES ES02775143T patent/ES2258652T3/es not_active Expired - Lifetime
- 2002-11-13 DO DO2002000512A patent/DOP2002000512A/es unknown
- 2002-11-22 GT GT200200236A patent/GT200200236A/es unknown
- 2002-11-25 PE PE2002001130A patent/PE20030738A1/es not_active Application Discontinuation
- 2002-11-25 TW TW091134190A patent/TW200300345A/zh unknown
- 2002-11-26 UY UY27548A patent/UY27548A1/es not_active Application Discontinuation
- 2002-11-27 AR ARP020104558A patent/AR037677A1/es unknown
- 2002-11-27 US US10/305,845 patent/US6794388B2/en not_active Expired - Fee Related
- 2002-11-27 HN HN2002000332A patent/HN2002000332A/es unknown
- 2002-11-28 SV SV2002001413A patent/SV2004001413A/es not_active Application Discontinuation
- 2002-11-29 PA PA20028559401A patent/PA8559401A1/es unknown
-
2004
- 2004-04-07 ZA ZA200402720A patent/ZA200402720B/en unknown
Also Published As
Publication number | Publication date |
---|---|
ATE320256T1 (de) | 2006-04-15 |
HN2002000332A (es) | 2003-12-11 |
UY27548A1 (es) | 2003-06-30 |
AR037677A1 (es) | 2004-12-01 |
US20030149044A1 (en) | 2003-08-07 |
MXPA04003192A (es) | 2004-07-27 |
EP1461040A1 (en) | 2004-09-29 |
CN1589148A (zh) | 2005-03-02 |
JP2005513032A (ja) | 2005-05-12 |
US6794388B2 (en) | 2004-09-21 |
TW200300345A (en) | 2003-06-01 |
KR20040066140A (ko) | 2004-07-23 |
WO2003045394A1 (en) | 2003-06-05 |
PA8559401A1 (es) | 2004-02-07 |
EP1461040B1 (en) | 2006-03-15 |
DE60209929D1 (de) | 2006-05-11 |
CA2468705A1 (en) | 2003-06-05 |
ZA200402720B (en) | 2005-05-18 |
BR0214559A (pt) | 2007-03-13 |
ES2258652T3 (es) | 2006-09-01 |
IL161326A0 (en) | 2004-09-27 |
RU2004116311A (ru) | 2005-03-27 |
DE60209929T2 (de) | 2006-11-16 |
AU2002341327A1 (en) | 2003-06-10 |
SV2004001413A (es) | 2004-05-07 |
PL374325A1 (en) | 2005-10-17 |
DOP2002000512A (es) | 2003-05-31 |
GT200200236A (es) | 2003-06-25 |
PE20030738A1 (es) | 2003-08-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP4196829B2 (ja) | 5,8,14−トリアザテトラシクロ[10.3.1.02,11.04,9]−ヘキサデカ−2(11),3,5,7,9−ペンタエンのコハク酸塩およびその医薬組成物 | |
US7265119B2 (en) | Tartrate salts of 5,8,14-triazatetracyclo[10.3.1.02,11.04.9]-hexadeca-2(11),3,5,7,9-pentaene and pharmaceutical compositions thereof | |
AU2002253482A1 (en) | Tartrate salts of 5,8,14-triazatetracyclo (10.3.102,11.04.9)-hexadeca-2(11),3,5,7,9-pentaene and pharmaceutical compositions thereof | |
US6787549B2 (en) | Citrate salt of 5,8,14-triazatetracyclo[10.3.1.02,11.04,9]-hexadeca-2(11),3,5,7,9-pentaene and pharmaceutical compositions thereof | |
EP3402796B1 (en) | 6,7,8,9-tetrahydro-5h-pyrido[2,3-d]azepine dopamine d3 ligands | |
KR20040063939A (ko) | 아릴 융합된 아자폴리시클릭 화합물 | |
KR100572430B1 (ko) | 치료적 화합물의 시트르산 염 및 그의 약제학적 조성물 | |
EP1534667B1 (en) | Muscarinic agonists | |
CN115724846A (zh) | 异喹啉磺酰衍生物新晶型及其制备方法和用途 | |
AU2002255219A1 (en) | The citrate salt of 5, 8, 14-triazatetracyclo(10.3.1.02,11,04.9)-hexadeca-2(11),3,5,7,9-pentaene and pharmaceutical compositions thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
RD02 | Notification of acceptance of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7422 Effective date: 20071003 |
|
RD04 | Notification of resignation of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7424 Effective date: 20071003 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20080520 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20080806 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20080916 |
|
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 |
|
RD03 | Notification of appointment of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7423 Effective date: 20080922 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20080922 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20111010 Year of fee payment: 3 |
|
R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
LAPS | Cancellation because of no payment of annual fees |